Anita Tuli-Kendall
Primary Care · Gaithersburg, MDNPI 1285064170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,527, 2.1 times the $721 reported in 2021. Among primary care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$935
- Indivior Inc.$575
- AbbVie$565
- Lilly USA, LLC$536
- USWM, LLC$410
- Exact Sciences$325
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,65598%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $935 |
| Indivior Inc. | 40 | $575 |
| AbbVie | 34 | $565 |
| Lilly USA, LLC | 24 | $536 |
| USWM, LLC | 31 | $410 |
| Exact Sciences | 13 | $325 |
| AstraZeneca(2 entities) | 12 | $262 |
| Braeburn Inc. | 11 | $258 |
| Astellas Pharma US Inc | 2 | $132 |
| Orexo US, Inc. | 6 | $129 |
| Axsome Therapeutics, Inc. | 4 | $110 |
| Boehringer Ingelheim | 3 | $82 |
| Amgen | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Alkermes, Inc. | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Merck | 3 | $43 |
| Bayer | 2 | $33 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $15 |
How this compares
$4,767 in reported general payments places this provider in the 95th percentile of 191 primary care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $146,459 |
| TrulicityDulaglutide | 42 | $93,189 |
| MounjaroTirzepatide | 40 | $78,058 |
| JardianceEmpagliflozin | 35 | $47,481 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $27,031 |
| FarxigaDapagliflozin Propanediol | 16 | $24,579 |
| SynthroidLevothyroxine Sodium | 28 | $3,071 |
| Atorvastatin Calcium | 152 | $1,988 |
| Rosuvastatin Calcium | 124 | $1,916 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 15 | $1,606 |
| Levothyroxine Sodium | 107 | $1,079 |
| Amlodipine Besylate | 120 | $856 |
| Gabapentin | 27 | $737 |
| Metoprolol Succinate | 38 | $729 |
| Omeprazole | 61 | $705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $536 | $171,24782 claims |
| Novo NordiskOzempic | $935 | $146,45966 claims |
| Boehringer IngelheimJardiance | $82 | $47,48135 claims |
| AstraZenecaFarxiga | $262 | $24,57916 claims |
| AbbVieSynthroid | $565 | $3,07128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 primary care providers in Maryland.
Other primary care in Gaithersburg
- Roza LissGaithersburg$5K
- Megan SchollenbergerGaithersburg$1K
- Olga VarnachevaGaithersburg$876
- Ashley SalamoneBaltimore$13K
- Ololade IkuomolaBaltimore$10K
- Patricia GoodmanUppr Marlboro$8K
- Jody LeonardAnnapolis$7K
- Yury MalachevskyBaltimore$7K
- Kyleen DavisChevy Chase$6K
- Laura Ferguson-WeigmanBel Air$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.